Current and emerging treatment options for patients with relapsed myeloma

Clinical Medicine Insights: Oncology

Volumn 7, Issue , 2013, Pages 209-219

  Castelli, Roberto ^a   Gualtierotti, Roberta ^a   Orofino, Nicola ^a   Losurdo, Agnese ^a   Gandolfi, Sara ^a   Cugno, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Chemotherapy; Immunomodulatory drugs (IMIDs); Proteasome inhibitors; Relapsed refractory multiple myeloma

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; ETOPOSIDE; GAMMA INTERFERON; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOMODULATING AGENT; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LENALIDOMIDE; LORVOTUZUMAB MERTANSINE; MAPATUMUMAB; MELPHALAN; MONOCLONAL ANTIBODY; PANOBINOSTAT; POMALIDOMIDE; PREDNISOLONE; PREDNISONE; SALINOSPORAMIDE A; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE ACTIVATION; BONE LESION; BONE MARROW; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL FEATURE; CONSTIPATION; CRYOPRESERVATION; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG RECHALLENGE; DRUG SAFETY; ENZYME INHIBITION; FATIGUE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERCALCEMIA; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LOW DRUG DOSE; MAINTENANCE THERAPY; MOLECULAR MECHANICS; MONOTHERAPY; MORBIDITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NATURAL KILLER T CELL; NAUSEA; NEUROPATHY; NEUTROPENIA; OSTEOCLASTOGENESIS; OVERALL SURVIVAL; PATIENT CARE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SEDATION; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOGENICITY; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VIRUS REACTIVATION;

EID: 84882722657     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S8014     Document Type: Review

References (76)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18): 1860-73.
2. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P; ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma. Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008;22(2):231-9.
3. Magrangeas F, Avet-Loiseau H, Gouraud W, etal. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia. 2013;27(2): 473-81.
4. Moreau P, Minvielle S. Multiple myeloma: so much progress, but so many unsolved questions. Haematologica. 2013;98(4):487-9.
5. Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol. 2011;86(1):1-15.
6. Moreau P. The future of therapy for relapsed/refractory multiple myeloma: emerging agents and novel treatment strategies. Semin Hematol. 2012; 49 Suppl 1:S33-46.
7. Castelli R, Cannavò A, Conforti F, Grava G, Cortelezzi A. Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice. Immunopharmacol Immunotoxicol. 2012;34(5):740-53.
8. Moehler T, Goldschmidt H. Therapy of relapsed and refractory multiple myeloma. Recent Results Cancer Res. 2011;183:239-71.
9. Attal M, Harousseau JL, Stoppa AM, etal. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335(2):91-7.
10. Harousseau JL, Dimopoulos MA, Wang M, etal. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica. 2010;95(10):1738-44.
11. Dimopoulos MA, Kastritis E, Christoulas D, etal. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia. 2010;24(10):1769-78.
12. Lonial S. Relapsed multiple myeloma. Hematology Am Soc Hematol Educ Program. 2010;2010:303-9.
13. Lokhorst H, Einsele H, Vesole D, etal; International Myeloma Working Group. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol. 2010;28(29):4521-30.
14. Bladé J, Rosiñol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood. 2010;115(18):3655-63.
15. Jimenez-Zepeda VH, Mikhael J, Winter A, etal. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival. Biol Blood Marrow Transplant. 2012;18(5):773-9.
16. Olin RL, Vogl DT, Porter DL, etal. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant. 2009;43(5):417-22.
17. Michaelis LC, Saad A, Zhong X, etal; Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013;19(5):760-6.
18. Morris C, Iacobelli S, Brand R, etal; Chronic Leukaemia Working Party Myeloma Subcommittee, European Group for Blood and Marrow Transplantation. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol. 2004;22(9):1674-81.
19. Quach H, Ritchie D, Steward AK, etal. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22-32.
20. Kneller A, Raanani P, Hardan I, etal. Therapy with thalidomide in refractory multiple myeloma patients-the revival of an old drug. Br J Haematol. 2000;108(2):391-3.
21. [No authors listed]. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 2000;342(5):364.
22. Mohty M, Attal M, Marit G, etal. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC). Bone Marrow Transplant. 2005;35(2):165-9.
23. Dimopoulos MA, Hamilos G, Zomas A, etal. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J. 2004;5(2):112-7.
24. García-Sanz R, González-Porras JR, Hernández JM, etal. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia. 2004;18(4):856-63.
25. Kropff M, Baylon HG, Hillengass J, etal. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012;97(5):784-91.
26. Dimopoulos M, Spencer A, Attal M, etal. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123-32.
27. Knop S, Gerecke C, Liebisch P, etal. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 2009;113(18):4137-43.
28. Schey SA, Morgan GJ, Ramasamy K, etal. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol. 2010;150(3):326-33.
29. Reece D, Masih-Khan. Phase I-II Trial of Oral Cyclophosphamide, Prednisone and Lenalidomide (Revlimid®) (CPR) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma. 50th ASH Annual Meeting and Exposition. 2010;116:3055.
30. Kastritis E, Dimopoulos MA. The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother. 2007;8(4): 497-509.
31. Castelli R, Cassin R, Cannavò A, Cugno M. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013;13(1):1-7.
32. Thieblemont C, Delfau-Larue MH, Coiffier B. Lenalidomide in diffuse large B-cell lymphoma. Adv Hematol. 2012;2012:861060.
33. Quach H, Ritchie D, etal. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22-32.
34. Schey S, Ramasamy K. Pomalidomide therapy for myeloma. Expert Opin Investig Drugs. 2011;20(5):691-700.
35. Lacy MQ, Allred JB, Gertz MA, etal. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 2011;118(11):2970-5.
36. Richardson PG, Siegel D, Baz R, etal. Phase 1study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013;121(11):1961-7.
37. Forsberg PA, Mark TM. Pomalidomide in the treatment of relapsed multiple myeloma. Future Oncol. 2013;9(7):939-48.
38. Richardson PG, Sonneveld P, Schuster M, etal. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007;110(10):3557-60.
39. Haynes R, Leung N, Kyle R, Winearls CG. Myeloma kidney: improving clinical outcomes? Adv Chronic Kidney Dis. 2012;19(5):342-51.
40. Dimopoulos MA, Roussou M, Gkotzamanidou M, etal. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013;27(2):423-9.
41. Bergsagel PL, Mateos MV, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood. 2013;121(6): 884-92.
42. Jagannath S, Richardson PG, Sonneveld P, etal. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia. 2007;21(1):151-7.
43. Neben K, Lokhorst HM, Jauch A, etal. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940-8.
44. Jagannath S, Barlogie B, Berenson JR, etal. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008;143(4):537-40.
45. Berenson JR, Yang HH, Sadler K, etal. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2006;24(6):937-44.
46. Orlowski RZ, Nagler A, Sonneveld P, etal. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892-901.
47. Kropff M, Bisping G, Schuck E, etal; Deutsche Studiengruppe Multiples Myelom. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138(3):330-7.
48. Palumbo A, Gay F, Bringhen S, etal. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Ann Oncol. 2008;19(6):1160-5.
49. Popat R, Oakervee H, Williams C, etal. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol. 2009;144(6):887-94.
50. Siegel DS, Martin T, Wang M, etal. A phase 2study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120(14):2817-25.
51. Jagannath S, Vij R, Stewart AK, etal. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012;12(5):310-8.
52. Cavo M, Tacchetti P, Patriarca F, etal; GIMEMA Italian Myeloma Network. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3study. Lancet. 2010;376(9758):2075-85.
53. Morabito F, Gentile M, Mazzone C, etal. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood. 2011;118(22):5759-66.
54. Richardson PG, Mitsiades CS, Laubach JP, etal. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013;37(7):829-37.
55. Lonial S, Vij R, Harousseau JL, etal. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol. 2012;30(16):1953-9.
56. Allegra A, Penna G, Alonci A, etal. Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. Eur J Haematol. 2013;90(6):441-68.
57. Lentzsch S, O'Sullivan A, Kennedy RC, etal. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood. 2012;119(20):4608-13.
58. Pönisch W, Heyn S, Beck J, etal. Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO-#077. Br J Haematol. 2013;162(2):202-9.
59. Cavo M, Zamagni E, Cellini C, etal. Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. Blood. 2002;100(6):2272-3.
60. Barbui T, Falanga A. Thalidomide and thrombosis in multiple myeloma. J Thromb Haemost. 2003;1(3):421-2.
61. Castelli R, Ferrari B, Cortelezzi A, Guariglia A. Thromboembolic complications in malignant haematological disorders. Curr Vasc Pharmacol. 2010;8(4):482-94.
62. Elice F, Rodeghiero F. Hematologic malignancies and thrombosis. Thromb Res. 2012;129(3):360-6.
63. Niesvizky R, Naib T, Christos PJ, etal. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol. 2007;138(5):640-3.
64. Thomas A, Mailankody S, Korde N, Kristinsson SY, Turesson I, Landgren O. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood. 2012;119(12):2731-7.
65. Adès L, Le Bras F, Sebert M, etal. Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies. Haematologica. 2012;97(2):213-8.
66. Palumbo A, Hajek R, Delforge M, etal. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69.
67. Chanan-Khan A, Sonneveld P, Schuster MW, etal. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008;26(29):4784-90.
68. Giles F, Fischer T, Cortes J, etal. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12(15):4628-35.
69. Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas J, Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol. 2012;40(7):564-74.
70. Jakubowiak A. Management strategies for relapsed/refractory multiple myeloma: current clinical perspectives. Semin Hematol. 2012;49 Suppl 1: S16-32.
71. Mill WB, Griffith R. The role of radiation therapy in the management of plasma cell tumors. Cancer. 1980;45(4):647-52.
72. Berenson JR, Lichtenstein A, Porter L, etal. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16(2):593-602.
73. Morgan GJ, Davies FE, Gregory WM, etal; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376(9757):1989-99.
74. Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M. Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents. Leukemia. 2012;26(1):73-85.
75. Chaudhry V, Cornblath DR, Polydefkis M, Ferguson A, Borrello I. Characteristics of bortezomib-and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst. 2008;13(4):275-82.
76. Larocca A, Cavallo F, Bringhen S, etal. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119(4):933-9; quiz 1093.